25,857 Shares in Glaukos Co. (NYSE:GKOS) Bought by Exome Asset Management LLC

Exome Asset Management LLC purchased a new stake in Glaukos Co. (NYSE:GKOS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 25,857 shares of the medical instruments supplier’s stock, valued at approximately $3,369,000. Glaukos accounts for 2.3% of Exome Asset Management LLC’s investment portfolio, making the stock its 16th biggest position.

Other institutional investors also recently modified their holdings of the company. Values First Advisors Inc. bought a new position in shares of Glaukos in the third quarter valued at about $25,000. Harvest Fund Management Co. Ltd grew its holdings in shares of Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares in the last quarter. Fifth Third Wealth Advisors LLC bought a new position in shares of Glaukos in the second quarter worth $187,000. KBC Group NV raised its stake in Glaukos by 16.2% in the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after purchasing an additional 201 shares in the last quarter. Finally, Brighton Jones LLC bought a new stake in Glaukos during the second quarter worth about $208,000. 99.04% of the stock is currently owned by institutional investors.

Insider Transactions at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gilbert H. Kliman sold 2,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total transaction of $288,020.00. Following the completion of the sale, the director now owns 32,336 shares in the company, valued at $4,656,707.36. This represents a 5.82 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

GKOS has been the subject of several analyst reports. Stephens upgraded shares of Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler set a $140.00 price target on Glaukos in a research note on Thursday, October 17th. Stifel Nicolaus raised their price objective on Glaukos from $145.00 to $153.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Truist Financial increased their target price on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Finally, Citigroup upgraded shares of Glaukos from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $132.00 to $162.00 in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $143.17.

Glaukos Stock Performance

GKOS stock opened at $138.82 on Friday. Glaukos Co. has a 1-year low of $65.00 and a 1-year high of $147.65. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The stock has a 50-day moving average price of $136.25 and a 200-day moving average price of $126.81. The firm has a market cap of $7.65 billion, a PE ratio of -45.97 and a beta of 1.03.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to the consensus estimate of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company’s quarterly revenue was up 23.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.50) EPS. As a group, equities research analysts expect that Glaukos Co. will post -1.89 earnings per share for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.